Discontinued — last reported Q4 '23
Pharmaceutical — Goodwill impairment
This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates a deterioration in the expected future cash flows or market competitiveness of the pharmaceutical segment, often signaling overpayment for past acquisitions or structural industry headwinds. A decrease or absence of impairment suggests that the segment's assets are performing in line with or exceeding the expectations set at the time of acquisition.
Detailed definition
This metric represents the non-cash charge recognized when the carrying amount of goodwill associated with the pharmaceu...
Peer comparison
Peer companies in the pharmaceutical wholesale and distribution industry periodically report similar impairment charges following large-scale acquisitions or shifts in generic drug pricing, making this a standard metric for assessing capital allocation discipline.
cah_segment_pharmaceutical_goodwill_impairmentHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cardinal Health's pharmaceutical — goodwill impairment?
- Cardinal Health (CAH) reported pharmaceutical — goodwill impairment of $0.00 in Q4 2023.
- What does pharmaceutical — goodwill impairment mean?
- The amount of value written off from the pharmaceutical segment's balance sheet because the acquired assets are worth less than originally estimated.